213 related articles for article (PubMed ID: 23521018)
1. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses.
Duintjer Tebbens RJ; Pallansch MA; Kalkowska DA; Wassilak SG; Cochi SL; Thompson KM
Risk Anal; 2013 Apr; 33(4):703-49. PubMed ID: 23521018
[TBL] [Abstract][Full Text] [Related]
2. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
3. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S412-23. PubMed ID: 25316863
[TBL] [Abstract][Full Text] [Related]
4. Circulating vaccine-derived polioviruses: current state of knowledge.
Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
[TBL] [Abstract][Full Text] [Related]
5. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
6. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
[TBL] [Abstract][Full Text] [Related]
7. Transmission dynamics of oral polio vaccine viruses and vaccine-derived polioviruses on networks.
Kim JH; Rho SH
J Theor Biol; 2015 Jan; 364():266-74. PubMed ID: 25264265
[TBL] [Abstract][Full Text] [Related]
8. Update on vaccine-derived polioviruses--worldwide, July 2009-March 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Jul; 60(25):846-50. PubMed ID: 21716199
[TBL] [Abstract][Full Text] [Related]
9. Modeling the dynamics of oral poliovirus vaccine cessation.
Thompson KM; Duintjer Tebbens RJ
J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
[TBL] [Abstract][Full Text] [Related]
10. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
[TBL] [Abstract][Full Text] [Related]
11. Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.
Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
PLoS One; 2015; 10(6):e0130123. PubMed ID: 26068928
[TBL] [Abstract][Full Text] [Related]
12. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
[TBL] [Abstract][Full Text] [Related]
13. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).
Duintjer Tebbens RJ; Pallansch MA; Kim JH; Burns CC; Kew OM; Oberste MS; Diop OM; Wassilak SG; Cochi SL; Thompson KM
Risk Anal; 2013 Apr; 33(4):680-702. PubMed ID: 23470192
[TBL] [Abstract][Full Text] [Related]
14. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
15. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India.
Kalkowska DA; Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S398-411. PubMed ID: 25316861
[TBL] [Abstract][Full Text] [Related]
16. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
Duintjer Tebbens RJ; Thompson KM
BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
[TBL] [Abstract][Full Text] [Related]
17. Update on vaccine-derived polioviruses--worldwide, April 2011-June 2012.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Sep; 61():741-6. PubMed ID: 22992572
[TBL] [Abstract][Full Text] [Related]
18. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
19. A developing country perspective on vaccine-associated paralytic poliomyelitis.
John TJ
Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
[TBL] [Abstract][Full Text] [Related]
20. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.
Ghendon Y; Robertson SE
Bull World Health Organ; 1994; 72(6):973-83. PubMed ID: 7867144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
